Evaluation of platelet parameters and neutrophil/lymphocyte ratio during omalizumab treatment in patients with severe chronic spontaneous urticaria

Basit Öğe Kaydı
dc.contributor.authorErtaş, Ragıp
dc.contributor.authorÖzyurt, Kemal
dc.contributor.authorKarakükçü, Çiğdem
dc.contributor.authorAkkuş, Muhammet Reşat
dc.contributor.authorÖzlü, Emin
dc.contributor.authorAvcı, Atıl
dc.contributor.authorAtasoy, Mustafa
dc.date.accessioned2020-05-01T12:14:52Z
dc.date.available2020-05-01T12:14:52Z
dc.date.issued2018
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionErtas, Ragip/0000-0002-9269-2619; Akkus, Muhammet Resat/0000-0002-7938-2173; Karakukcu, Cigdem/0000-0001-9858-3272en_US
dc.descriptionWOS: 000452890300026en_US
dc.descriptionPubMed: 30541255en_US
dc.description.abstractBackground/aim: Spontaneous wheals and/or angioedema lasting longer than six weeks are described as chronic spontaneous urticaria (CSU). Omalizumab is used for the treatment of antihistamine-resistant CSU. The neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), mean platelet volume (MPV), and platelet distribution width (PDW) are considered important indicators of inflammation and platelet activation in chronic diseases. We aimed to determine the NLR, PLR, MPV, and PDW levels in patients with CSU compared with healthy controls. We also aimed to investigate the effects of omalizumab therapy on these parameters in CSU patients. Materials and methods: This hospital-based, retrospective study included 143 patients with CSU and 132 healthy controls with a mean age of 40.0 +/- 13.17 and 42.0 +/- 16.34, respectively. Patients with equal or higher-than-baseline UAS scores at week 12 of omalizumab treatment were considered nonresponders, others were considered responders. We analyzed the neutrophils, lymphocytes, platelet counts, NLR, PLR, MPV, and PDW before, during, and after omalizumab treatment and compared the results with those of healthy controls. Results: CSU patients presented higher baseline MPV (P = 0.035) and lower baseline PDW values (P < 0.001) than healthy controls. There were statistically significant increases in the MPV (P < 0.001), MPV/platelet count (P = 0.005), and PDW (P = 0.003) and there was a statistically significant decrease in the NLR (P = 0.018) during omalizumab treatment. The percent increase of MPV was low in nonresponders (P = 0.009). Nonresponders had lower PDW values than responders (P = 0.040). Conclusion: The increase in the MPV and PDW may be due to platelet activation during omalizumab treatment. The decrease in the NLR may be regarded as an antiinflammatory effect of omalizumab. The effect of omalizumab on platelet and inflammatory markers may be used to discriminate the responders from nonresponders.en_US
dc.identifier.doi10.3906/sag-1803-87en_US
dc.identifier.endpage1262en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue6en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1255en_US
dc.identifier.urihttps://doi.org/10.3906/sag-1803-87
dc.identifier.urihttps://hdl.handle.net/20.500.12684/6377
dc.identifier.volume48en_US
dc.identifier.wosWOS:000452890300026en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technical Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal Of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic spontaneous urticariaen_US
dc.subjectinflammationen_US
dc.subjectplateleten_US
dc.subjectMPVen_US
dc.subjectPDWen_US
dc.subjectNLRen_US
dc.subjectPLRen_US
dc.subjectomalizumaben_US
dc.titleEvaluation of platelet parameters and neutrophil/lymphocyte ratio during omalizumab treatment in patients with severe chronic spontaneous urticariaen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
6377.pdf
Boyut:
708.19 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu